MannKind (MNKD) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MannKind (MNKD) has outperformed Vor Biopharma (VOR) over the past year, losing 38.9% versus a loss of 44.4%. Over five years, MNKD leads with a -32.2% price change compared with -93.9% for VOR. Vor Biopharma is the larger company by market cap ($1.13 billion vs $1.10 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNKD | VOR |
|---|---|---|
| Share price | $3.42 | $19.13 |
| Market cap | $1.10B | $1.13B |
| 1-day change | -0.87% | +1.86% |
| YTD return | -39.15% | +43.58% |
| 1-year return | -38.94% | -44.44% |
| 5-year return | -32.22% | -93.93% |
| P/E ratio (TTM) | — | 0.11 |
| Forward P/E | 26.82 | — |
| EPS (TTM) | $-0.14 | $180.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.51 | $33.50 |
| 52-week low | $2.23 | $6.50 |
| Distance from 52-week high | -47.47% | -42.90% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +129.24% | +103.87% |
| Average volume | 4.48M | 992.56K |
| Shares outstanding | 321.54M | 59.16M |
| Employees | 591 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees
MNKD vs VOR FAQ
Which is bigger, MannKind or Vor Biopharma?
Vor Biopharma (VOR) is larger, with a market capitalization of $1.13B compared with $1.10B for MannKind (MNKD).
Which stock has performed better over the past year, MNKD or VOR?
MNKD returned -38.94% over the past 12 months, compared with -44.44% for VOR (price return, excluding dividends). Past performance does not predict future results.
Are MannKind and Vor Biopharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for MannKind and Biotechnology: Biological Products (No Diagnostic Substances) for Vor Biopharma.